Guardant Health (GH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Nove ...

Guardant Health needs cash. Until it can get it from selling enough services, it must sell its own shares instead. Shares of precision medicine company Guardant Health (GH -11.13%), which specializes in liquid biopsies to test for cancer, fell 10.6% through 10:05 a.m. ET Monday morning. Monday was the first trading day in which investors got to react to a Guardant announcement late Friday, that it plans to sell stock and raise $400 million in new cash to fund its operations. Guardant needs money Guardant's ...

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. The 20-day moving ...

Financial Data and Key Metrics Changes - Total revenue grew 29% to $177.2 million, driven by precision oncology revenue, which increased 33% to $166.5 million [16][23] - Clinical test volume reached a record 49,400 tests in Q2 2024, with a year-over-year growth of 14% [16][23] - Non-GAAP gross margin excluding screening was 62%, down from 64% in Q2 2023 due to test and revenue mix [27] - Registered EBITDA loss was $61.9 million, a decrease of $23.3 million from $85.2 million in Q2 2023 [28] Business Line Data and Key Metrics Changes - Precision oncology revenue from clinical tests increased 30% to $130.2 million [23] - Biopharma revenue grew 45% to $36.2 million, with a record 10,475 tests performed, reflecting a 56% year-over-year increase [16][24] - The launch of Guardant360 LVT provided a significant upgrade, covering 739 genes and quantifying tumor burden with greater sensitivity [17] Market Data and Key Metrics Changes - The Shield blood test for colorectal cancer screening is now available, addressing a market opportunity of 120 million average-risk individuals aged 45 to 84 [9][10] - Medicare coverage for Shield represents a 15 million annual testing opportunity, contributing to a multi-billion dollar market [9][10] - The company anticipates continued growth in clinical volume, expecting approximately 20% growth for the full year 2024 [23] Company Strategy and Development Direction - The company aims to exceed 1 million Shield tests by 2028, bolstered by FDA approval and Medicare coverage [10][11] - Guardant Health is focused on building a sustainable and profitable business model, emphasizing the value of its tests in improving health outcomes [45] - The company plans to ramp up its sales force to 100 by the end of the year to support the Shield launch [61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term viability of Shield, citing its first-mover advantage and robust clinical evidence [36][39] - The company is optimistic about achieving cash flow breakeven by 2028, with over $1 billion in cash reserves [29][30] - Management highlighted the importance of ongoing clinical studies and publications to support future Medicare coverage and guideline inclusion [49] Other Important Information - The company is actively managing cash burn and expects to achieve gross margin positivity for its MRD business by 2025 [21][31] - The recent FDA approval of Shield is seen as a historic milestone for both the company and the liquid biopsy field [13] Q&A Session Summary Question: Expectations on Medicare coverage in the CRC surveillance space - Management confirmed existing coverage for Guardant Reveal and expressed optimism about obtaining additional coverage for surveillance settings based on recent study outcomes [33][34] Question: Potential for ADLT status on Shield - Management indicated that ADLT designation is expected in 2025, contingent on meeting clear criteria [35][36] Question: Insights on Shield's competitive position - Management emphasized the significant barriers for competitors to achieve similar FDA approvals and performance metrics, reinforcing Shield's market position [38][39] Question: Biopharma business performance and guidance - Management noted strong uptake of Guardant Infinity and a healthy pipeline, leading to an increase in biopharma revenue growth expectations for 2024 [40][42] Question: Rationale behind Shield's pricing strategy - Management justified the pricing based on the health outcome benefits and the economic value of the test, asserting that it reflects the test's value in the marketplace [44][45] Question: Marketing plans for Shield - Management outlined a direct sales approach to promote Shield, leveraging media attention and focusing on educating physicians and patients about the test [63][66]

Wall Street analysts forecast that Guardant Health (GH) will report quarterly loss of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 14.9%. It is anticipated that revenues will amount to $161.93 million, exhibiting an increase of 18.1% compared to the year-ago quarter. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial p ...

signal a downward trend. After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving ave ...

After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common movin ...

Group 1 - Guardant Health (GH) has recently reached a key level of support and has overtaken the 200-day moving average, indicating a long-term bullish trend [1] - GH has moved 47.1% higher over the last four weeks, suggesting potential for another rally [2] - The company has a Zacks Rank 3 (Hold) and has seen positive earnings estimate revisions, with 5 higher estimates compared to none lower for the current fiscal year [2] Group 2 - Investors are encouraged to consider adding GH to their watchlist due to the important technical indicator and positive earnings estimate revisions [3]

Guardant Health (GH) stock rocketed Friday after a Food and Drug Administration panel recommended the agency approve Guardant's blood-based colon cancer screening test. X The FDA's Medical Devices Advisory Committee voted eight to one that Guardant's blood-based test, known as Shield, is safe. Six out of nine panelists said the test appears effective, and seven to two voted that the benefits outweigh the risks. If approved, Guardant's blood-based test would rival Exact Sciences' (EXAS) Cologuard, an already ...

For the quarter ended March 2024, Guardant Health (GH) reported revenue of $168.49 million, up 30.9% over the same period last year. EPS came in at -$0.46, compared to -$1.30 in the year-ago quarter.The reported revenue represents a surprise of +11.94% over the Zacks Consensus Estimate of $150.51 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +36.11%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...